Elanco Animal Health Incorporated (ELAN) Spending and interest coverage
- R&D / revenue · 12 months: Value 7.39%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.47%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 7.39% | Research and development expense / revenue. Period ending 2026-06-30. $371.00M ÷ $5.02B × 100 ≈ 7.39% |
| Stock-based compensation / revenue · 12 months | 1.47% | Share-based compensation / revenue. Period ending 2026-06-30. $74.00M ÷ $5.02B × 100 ≈ 1.47% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 371.00M USD | Research and Development Expense |
| Revenue | 5.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 74.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $371.00M | $5.02B | $74.00M | (m) | (m) | 7.39% | 1.47% | (m) | (m) |
| 2026-03-31 | $371.00M | $4.89B | $74.00M | (m) | (m) | 7.58% | 1.51% | (m) | (m) |
| 2025-12-31 | $368.00M | $4.71B | $68.00M | (m) | (m) | 7.80% | 1.44% | (m) | (m) |
| 2025-09-30 | $356.00M | $4.59B | $67.00M | (m) | (m) | 7.75% | 1.46% | (m) | (m) |
| 2025-06-30 | $354.00M | $4.48B | $65.00M | (m) | (m) | 7.89% | 1.45% | (m) | (m) |
| 2025-03-31 | $351.00M | $4.43B | $59.00M | (m) | (m) | 7.93% | 1.33% | (m) | (m) |
| 2024-12-31 | $344.00M | $4.44B | $55.00M | (m) | (m) | 7.75% | 1.24% | (m) | (m) |
| 2024-09-30 | $342.00M | $4.45B | $55.00M | (m) | $256.00M | 7.68% | 1.23% | (m) | Reported |
| 2024-06-30 | $341.00M | $4.49B | $50.00M | (m) | $270.00M | 7.59% | 1.11% | (m) | Reported |
| 2024-03-31 | $333.00M | $4.37B | $45.00M | (m) | $279.00M | 7.63% | 1.03% | (m) | Reported |
| 2023-12-31 | $327.00M | $4.42B | $46.00M | (m) | $277.00M | 7.40% | 1.04% | (m) | Reported |
| 2023-09-30 | $328.00M | $4.37B | $46.00M | (m) | $272.00M | 7.51% | 1.05% | (m) | Reported |
| 2023-06-30 | $320.00M | $4.32B | $49.00M | (m) | $260.00M | 7.40% | 1.13% | (m) | Reported |
| 2023-03-31 | $321.00M | $4.44B | $57.00M | (m) | $253.00M | 7.23% | 1.28% | (m) | Reported |
| 2022-12-31 | $321.00M | $4.41B | $59.00M | (m) | $241.00M | 7.28% | 1.34% | (m) | Reported |
| 2022-09-30 | $333.00M | $4.54B | $62.00M | (m) | $234.00M | 7.33% | 1.36% | (m) | Reported |
| 2022-06-30 | $349.00M | $4.65B | $66.00M | (m) | $234.00M | 7.51% | 1.42% | (m) | Reported |
| 2022-03-31 | $361.00M | $4.75B | $65.00M | (m) | $227.00M | 7.60% | 1.37% | (m) | Reported |
| 2021-12-31 | $369.00M | $4.76B | $66.00M | (m) | $236.00M | 7.74% | 1.39% | (m) | Reported |
| 2021-09-30 | $390.00M | $4.79B | $64.70M | (m) | $241.80M | 8.14% | 1.35% | (m) | Reported |
| 2021-06-30 | $384.00M | $4.55B | $59.70M | (m) | $229.80M | 8.44% | 1.31% | (m) | Reported |
| 2021-03-31 | $349.00M | $3.86B | $51.70M | (m) | $194.80M | 9.05% | 1.34% | (m) | Reported |
| 2020-12-31 | $327.00M | $3.27B | $47.70M | (m) | $149.80M | 9.99% | 1.46% | (m) | Reported |
| 2020-09-30 | $281.60M | $2.92B | $43.80M | (m) | $108.10M | 9.64% | 1.50% | (m) | Reported |
| 2020-06-30 | $263.40M | $2.80B | $46.90M | (m) | $78.70M | 9.40% | 1.67% | (m) | Reported |
| 2020-03-31 | $272.80M | $3.00B | $52.80M | (m) | $74.60M | 9.10% | 1.76% | (m) | Reported |
| 2019-12-31 | $270.10M | $3.07B | $49.40M | (m) | $78.90M | 8.80% | 1.61% | (m) | Reported |
| 2019-09-30 | $263.90M | $3.08B | $42.50M | (m) | $81.20M | 8.56% | 1.38% | (m) | Reported |
| 2019-06-30 | $252.90M | $3.07B | $34.60M | (m) | $71.10M | 8.23% | 1.13% | (m) | Reported |
| 2019-03-31 | $245.50M | $3.06B | $26.80M | (m) | $50.40M | 8.02% | 0.88% | (m) | Reported |
| 2018-12-31 | $246.60M | $3.07B | $26.00M | (m) | $29.60M | 8.04% | 0.85% | (m) | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | Reported |
| 2018-03-31 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | Reported |
| 2017-12-31 | $251.70M | $2.89B | $25.00M | (m) | $0.00 | 8.71% | 0.87% | (m) | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $265.80M | $2.91B | $20.40M | (m) | $0.00 | 9.12% | 0.70% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |